VIA Pharmaceuticals (OTCPK:VIAP) - Stock Price, News & Analysis

VIAP Stock Overview

A development stage biotechnology company, focuses on the development of compounds for the treatment of cardiovascular and metabolic diseases. More details

VIAP fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	0/6
Dividends	0/6

Risk Analysis

Does not have a meaningful market cap ($20)

Latest financial reports are more than a year old

Shares are highly illiquid

VIA Pharmaceuticals, Inc. Competitors

DermTech

OTCPK:DMTK.Q

US$35.0

eFFECTOR Therapeutics

OTCPK:EFTR

US$940.0

Plant-Based Investment

OTCPK:CWWB.F

US$27.0

PLx Pharma Winddown

OTCPK:PLXP.Q

US$30.0

Price History & Performance

Summary of all time highs, changes and price drops for VIA Pharmaceuticals
Historical stock prices
Current Share Price	US$0.000001
52 Week High	US$0.0001
52 Week Low	US$0.000001
Beta	0
11 Month Change	0%
3 Month Change	0%
1 Year Change	n/a
33 Year Change	0%
5 Year Change	-99.98%
Change since IPO	-100.00%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	VIAP	US Biotechs	US Market
7D	0%	4.3%	1.6%
1Y	n/a	18.8%	32.3%

Return vs Industry: Insufficient data to determine how VIAP performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how VIAP performed against the US Market.

Price Volatility

Is VIAP's price volatile compared to industry and market?
VIAP volatility
VIAP Average Weekly Movement	n/a
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

Stable Share Price: VIAP's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine VIAP's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2004	n/a	n/a	n/a

VIA Pharmaceuticals, Inc., a development stage biotechnology company, focuses on the development of compounds for the treatment of cardiovascular and metabolic diseases. It is developing a pipeline of small molecule drugs that target the underlying causes of cardiovascular and metabolic diseases, including vascular inflammation, high cholesterol, high triglycerides, and insulin sensitization/diabetes. The company’s drug development pipeline includes VIA-3196, a Phase-1 ready liver-directed thyroid hormone receptor (THR) beta agonist that targets dyslipidemia, such as high LDL cholesterol, high triglycerides, and elevated Lp(a); Diacylglycerol Acyl Transferase 1 (DGAT1) inhibitor, which is in pre-clinical development stage treatment of type 2 diabetes with upside potential in weight control and dyslipidemia; and VIA-2291, a 5-Lipoxygenase inhibitor that has completed third Phase 2 clinical trial for the treatment of atherosclerotic plaque, an underlying cause of heart attack, stroke, and other vascular diseases.

VIA Pharmaceuticals, Inc. Fundamentals Summary

How do VIA Pharmaceuticals's earnings and revenue compare to its market cap?
VIAP fundamental statistics
Market cap	US$20.00
Earnings (TTM)	-US$9.60m
Revenue (TTM)	n/a

0.0x

P/S Ratio

0.0x

P/E Ratio

Is VIAP overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VIAP income statement (TTM)
Revenue	US$0
Cost of Revenue	US$0
Gross Profit	US$0
Other Expenses	US$9.60m
Earnings	-US$9.60m

Last Reported Earnings

Dec 31, 2010

Next Earnings Date

n/a

Earnings per share (EPS)	0
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0.0%

How did VIAP perform over the long term?

See historical performance and comparison